Systemic Manifestations and Mortality Risk in Transthyretin V142I Variant Carriers: A Million Veteran Program Analysis | JACC: CardioOncology
Feb 17, 2026•3 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
This study analyzes over 2,600 transthyretin V142I variant carriers in the Million Veteran Program and finds significantly elevated risks of heart failure, cardiomyopathy, arrhythmias, neuropathy, and musculoskeletal complications compared with matched controls. Despite these risks, amyloidosis was rarely diagnosed clinically, underscoring major gaps in recognition and the need for earlier identification and multidisciplinary intervention.
For the best experience, listen in Metacast app for iOS or Android